42 results
diagnosis management syndrome differential sle erythematosus systemic algorithm dermatology doac druginduced table anemia anticoagulation cancer chemotherapy comparison disease hcq hydroxychloroquine
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
old, ~10,000 new cases ... diagnosis and risk-stratification ... • Risks: infection ... only curative treatment ... #hematology #oncology
CNS Manifestations of Systemic Lupus Erythematosus (SLE) Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
CNS Manifestations ... autoantibodies that will cause ... Puncture, EEG Treatment ... #neurology #rheumatology ... diagnosis #management #treatment
Causes of Diffuse Lymphadenopathy - Differential Diagnosis Algorithm Reactive: - Systemic Inflammatory •
Causes of Diffuse ... • Systemic Lupus ... Diagnosis #Algorithm #Causes ... #Hematology #Oncology
Hydroxychloroquine - Risks and Benefits in Lupus Benefits: ↓ Disease activity, ↓ Flare, ↓ Damage, ↓ Corticosteroid dose,
Hydroxychloroquine - Risks ... and Benefits in Lupus ... #Benefits #Lupus ... #pharmacology # ... #sideeffects #rheumatology
Hydroxychloroquine Serum Measurement in SLE • Terminal elimination half-life = 40 days ([HCQI reflects long-term intake)
suspected) • In case ... • Special cases ... Measurement #SLE #rheumatology ... #pharmacology # ... levels #lupus #management
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Systemic Lupus Erythematosus ... , oral ulcers, Lupus ... Positive in 60-80% of cases ... life-threatening • Treatment ... Management #Summary #rheumatology
Treatment algorithm for VTE in Malignancy (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
patients at high risk ... interactions and bleeding risk ... also balance the risk ... Anticoagulation #Management #Hematology ... #Oncology
Tranexamic Acid - Indications and Pharmacology Pharmacokinetics: • MOA: Inhibits plasminogen activation to plasmin & inhibits fibrinolysis
Indications and Pharmacology ... : Urine Common Uses ... fatigue; Increases risk ... #Indications #Pharmacology ... #hematology
Drug Induced Lupus vs SLE Drug Induced Lupus (DIL): • Epidemiology: -10% of all lupus cases, drug-dependent,
cases, drug-dependent ... constitutional symptoms • Treatment ... Discontinuation of causal ... life-threatening • Treatment ... comparison #table #rheumatology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis. Currently, edoxaban and rivaroxaban are the only
Patient risk stratification ... algorithm for the treatment ... Anticoagulation #Management #Hematology ... #Oncology
►
No results found for "PNS hematology causes risk rheumatology treatment lupus oncology pharmacology"
Try removing search terms or sorting by relevance
Or Upload an image for you and others searching for #PNS #hematology #causes #risk #rheumatology #treatment #lupus #oncology #pharmacology